Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of Vibecotamab (XmAb14045), a CD123 x CD3 T Cell-Engaging Bispecific Antibody; Initial Results of a Phase 1 Study

被引：48
|
作者：
Ravandi, Farhad
Bashey, Asad
Stock, Wendy
Foran, James M.
Mawad, Raya
Egan, Daniel
Blum, William
Yang, Allen
Pastore, Alessandro
Johnson, Chelsea
Zheng, Shuo
Yilmaz, Musa
Mims, Alice S.
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-134746
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Initial Results of a Phase I Study of TNB-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Relapsed/Refractory Multiple Myeloma
    Rodriguez, Cesar
    D'Souza, Anita
    Shah, Nina
    Voorhees, Peter M.
    Ben Buelow
    Vij, Ravi
    Kumar, Shaji K.
    BLOOD, 2020, 136
  • [22] A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
    Uckun, Fatih M.
    Lin, Tara L.
    Mims, Alice S.
    Patel, Prapti
    Lee, Cynthia
    Shahidzadeh, Anoush
    Shami, Paul J.
    Cull, Elizabeth
    Cogle, Christopher R.
    Watts, Justin
    CANCERS, 2021, 13 (16)
  • [23] Updated Results from a Phase 1 Study of APVO436, a Novel Bispecific Anti-CD123 x Anti-CD3 Adaptir T Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
    Watts, Justin
    Maris, Michael
    Lin, Tara L.
    Patel, Prapti
    Madanat, Yazan F.
    Cogle, Christopher R.
    Borthakur, Gautam
    Huebner, Dirk
    Khaskhely, Noor
    Bonham, Lynn
    Massaro, Monica
    Taylor, Daphne
    Taromino, Caroline
    Mims, Alice S.
    BLOOD, 2022, 140 : 6204 - 6205
  • [24] Preliminary Results from a Phase 1 Study of APVO436, a Novel Anti-CD123 x Anti-CD3 Bispecific Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
    Watts, Justin M.
    Lin, Tara
    Wang, Eunice S.
    Mims, Alice S.
    Cull, Elizabeth H.
    Patel, Prapti A.
    Shami, Paul J.
    Walter, Roland B.
    Cogle, Christopher R.
    Chenault, Ruth A.
    Macpherson, Bret
    Chunyk, Allison Given
    McMahan, Catherine J.
    Gross, Jane A.
    Stromatt, Scott
    BLOOD, 2020, 136
  • [25] Updated results of a phase 1, first-in-human study of ABBV-383, a BCMA x CD3 bispecific T-cell redirecting antibody, in patients with relapsed/refractory multiple myeloma
    Voorhees, Peter
    Shah, Nina
    D'Souza, Anita
    Rodriguez, Cesar
    Weisel, Katja
    Teipel, Raphael
    Hurd, David
    Bueno, Orlando
    Pumford, Neil
    Rosenberg, Tanya
    Pothacamury, Rajvineeth Kumar
    Ross, Jeremy
    Polepally, Akshanth
    Lee, Shane
    Jin, Ziyi
    Talati, Chetasi
    Kumar, Shaji
    Vij, Ravi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S34 - S34
  • [26] A Phase I/IIa Study of Lemzoparlimab, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Initial Phase I Results
    Qi, Junyuan
    Li, Jian
    Jiang, Bin
    Jiang, Bo
    Liu, Hongzhong
    Cao, Xinxin
    Zhang, Meixiang
    Meng, Yuan
    Ma, Xiaoyu
    Jia, Yingmin
    Guo, Jiyuan
    Zhang, Yanni
    Huang, Wei
    Wang, Jianxiang
    BLOOD, 2020, 136
  • [27] Updated phase 1 results of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM).
    Krishnan, Amrita Y.
    Garfall, Alfred L.
    Mateos, Maria-Victoria
    van de Donk, Niels W. C. J.
    Nahi, Hareth
    San-Miguel, Jesus F.
    Oriol, Albert
    Rosinol, Laura
    Chari, Ajai
    Bhutani, Manisha
    Karlin, Lionel
    Benboubker, Lotfi
    Pei, Lixia
    Verona, Raluca
    Girgis, Suzette
    Stephenson, Tara
    Goldberg, Jenna D.
    Banerjee, Arnob
    Usmani, Saad Zafar
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [28] Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM)
    Garfall, Alfred L.
    Usmani, Saad Z.
    Mateos, Maria-Victoria
    Nahi, Hareth
    van de Donk, Niels W. C. J.
    San-Miguel, Jesus F.
    Rocafiguera, Albert Oriol
    Rosinol, Laura
    Chari, Ajai
    Bhutani, Manisha
    Pei, Lixia
    Verona, Raluca
    Girgis, Suzette
    Stephenson, Tara
    Goldberg, Jenna D.
    Banerjee, Arnob
    Krishnan, Amrita
    BLOOD, 2020, 136
  • [29] Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE® (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
    Subklewe, Marion y
    Stein, Anthony
    Walter, Roland B.
    Bhatia, Ravi
    Wei, Andrew H.
    Ritchie, David
    Bucklein, Veit
    Vachhani, Pankit
    Dai, Tian
    Hindoyan, Antreas
    Agarwal, Suresh
    Anderson, Abraham
    Khaldoyanidi, Sophia
    Ravandi, Farhad
    BLOOD, 2019, 134
  • [30] Updated Results From the Phase 1/2 MajesTEC-1 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma
    Popat, Rakesh
    Usmani, Saad Z.
    Garfall, Alfred
    van de Donk, Niels
    Nahi, Hareth
    San-Miguel, Jesus F.
    Oriol, Albert
    Nooka, Ajay
    Martin, Thomas
    Rosinol, Laura
    Chari, Ajai
    Karlin, Lionel
    Benboubker, Lotfi
    Mateos, Maria-Victoria
    Bahlis, Nizar
    Moreau, Philippe
    Besemer, Britta
    Martinez-Lopez, Joaquin
    Sidana, Surbhi
    Pei, Lixia
    Trancucci, Danielle
    Verona, Raluca
    Girgis, Suzette
    Olyslager, Yunsi
    Jaffe, Mindy
    Uhlar, Clarissa
    Stephenson, Tara
    Van Rampelbergh, Rian
    Banerjee, Arnob
    Goldberg, Jenna D.
    Kobos, Rachel
    Krishnan, Amrita
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 35 - 36
12345